ALK and non-small cell lung carcinoma: Targeted therapy, tyrosine kinase inhibitors (TKI), can prolong survival to 40 months, especially in epidermal growth factor receptor (EGFR) gene mutation and anaplastic lymphoma kinase (ALK) rearrangement NSCLC.